Table 4.
Results of diagnostic instruments
| M | SD | N | F | dfM | dfR | p | ω 2 | |
|---|---|---|---|---|---|---|---|---|
|
Primary outcome
|
|
|
|
|
|
|
|
|
|
CDRS-R |
|
|
|
|
|
|
|
|
| Pre-test |
53.80 |
12.24 |
15 |
|
|
|
|
|
| Post-test |
45.93 |
12.11 |
15 |
|
|
|
|
|
| Follow-up |
40.75 |
14.39 |
12 |
11.76 |
1 |
11.92 |
.005** |
.11 |
|
Secondary outcomes
|
|
|
|
|
|
|
|
|
|
BDI-II |
|
|
|
|
|
|
|
|
| Pre-test |
26.64 |
14.00 |
14 |
|
|
|
|
|
| Post-test |
20.67 |
13.45 |
15 |
|
|
|
|
|
| Follow-up |
14.50 |
9.98 |
12 |
11.19 |
1 |
31.97 |
.002** |
.01 |
|
IQLC |
|
|
|
|
|
|
|
|
| Pre-test |
20.60 |
3.85 |
15 |
|
|
|
|
|
| Post-test |
19.13 |
4.03 |
15 |
|
|
|
|
|
| Follow-up |
18.42 |
4.19 |
12 |
5.27 |
1 |
30.57 |
.03* |
.03 |
|
HoNOSCA |
|
|
|
|
|
|
|
|
| Pre-test |
13.60 |
5.88 |
15 |
|
|
|
|
|
| Post-test |
13.14 |
6.02 |
14 |
|
|
|
|
|
| Follow-up |
9.25 |
5.14 |
12 |
4.54 |
1 |
36.92 |
.04* |
.04 |
|
FBB-DES |
|
|
|
|
|
|
|
|
| Pre-test |
21.93 |
14.18 |
15 |
|
|
|
|
|
| Post-test |
23.31 |
12.30 |
13 |
|
|
|
|
|
| Follow-up |
17.11 |
7.90 |
9 |
.94 |
1 |
27.02 |
.34 |
.01 |
|
CGI-S |
|
|
|
|
|
|
|
|
| Pre-test |
4.00 |
1.07 |
15 |
|
|
|
|
|
| Post-test |
4.00 |
1.00 |
15 |
|
|
|
|
|
| Follow-up | 3.33 | 1.56 | 12 | 2.11 | 1 | 14.37 | .17 | .01 |
Notes * p < .05, ** p < .01; high mean values demonstrate a higher symptom severity; Explanation of abbreviations: M = mean; SD = standard deviation; N = number of participants; dfM = degrees of freedom for the effect of the model; dfR = degrees of freedom for the residuals of the model; effect sizes were analysed according to ANOVA with repeated measurements; ω2 = omega squared effect size; Interpretation of the effect size ω2: .01 ≤ ω2 < .06 – small effect; .06 ≤ ω2 < .15 – moderate effect; ω2 ≥ .15 – large effect.